Biophytis S.A. (ALBPS) - Net Assets
Based on the latest financial reports, Biophytis S.A. (ALBPS) has net assets worth €-7.82 Million EUR (≈ $-9.14 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.62 Million ≈ $7.74 Million USD) and total liabilities (€14.44 Million ≈ $16.88 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Biophytis S.A. (ALBPS) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-7.82 Million |
| % of Total Assets | -118.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | -242.01% |
| 10-Year Change | -183.16% |
| Growth Volatility | 221.91 |
Biophytis S.A. - Net Assets Trend (2012–2024)
This chart illustrates how Biophytis S.A.'s net assets have evolved over time, based on quarterly financial data. Also explore how large is Biophytis S.A.'s balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Biophytis S.A. (2012–2024)
The table below shows the annual net assets of Biophytis S.A. from 2012 to 2024. For live valuation and market cap data, see ALBPS company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-9.70 Million ≈ $-11.34 Million |
-149.47% |
| 2023-12-31 | €-3.89 Million ≈ $-4.55 Million |
-103.51% |
| 2022-12-31 | €-1.91 Million ≈ $-2.23 Million |
-133.50% |
| 2021-12-31 | €5.71 Million ≈ $6.67 Million |
-16.50% |
| 2020-12-31 | €6.83 Million ≈ $7.99 Million |
+190.78% |
| 2019-12-31 | €-7.53 Million ≈ $-8.80 Million |
-207.42% |
| 2018-12-31 | €7.01 Million ≈ $8.19 Million |
-66.93% |
| 2017-12-31 | €21.19 Million ≈ $24.77 Million |
+368.82% |
| 2016-12-31 | €4.52 Million ≈ $5.28 Million |
-61.26% |
| 2015-12-31 | €11.67 Million ≈ $13.64 Million |
+1133.40% |
| 2014-12-31 | €-1.13 Million ≈ $-1.32 Million |
-175.79% |
| 2013-12-31 | €-409.32K ≈ $-478.54K |
-425.91% |
| 2012-12-31 | €125.60K ≈ $146.83K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biophytis S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1038400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €734.00K | % |
| Other Comprehensive Income | €-15.30 Million | % |
| Other Components | €15.28 Million | % |
| Total Equity | €-9.67 Million | 100.00% |
Biophytis S.A. Competitors by Market Cap
The table below lists competitors of Biophytis S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Value & Income Trust
LSE:VIP
|
$1.03 Million |
|
Trifast plc
LSE:TRI
|
$1.03 Million |
|
PDG Realty S.A. Empreendimentos e Participações
SA:PDGR3
|
$1.03 Million |
|
Inspecs Group plc
LSE:SPEC
|
$1.03 Million |
|
Boxlight Corp Class A
NASDAQ:BOXL
|
$1.03 Million |
|
Thiensurat Public Company Limited
BK:TSR
|
$1.03 Million |
|
Shield Therapeutics plc
LSE:STX
|
$1.03 Million |
|
Protagenic Therapeutics
NASDAQ:PTIX
|
$1.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biophytis S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,857,000 to -9,668,000, a change of -5,811,000.
- Net loss of 10,379,000 reduced equity.
- Other comprehensive income decreased equity by 15,276,999.
- Other factors increased equity by 19,844,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.38 Million | -107.35% |
| Other Comprehensive Income | €-15.28 Million | -158.02% |
| Other Changes | €19.84 Million | +205.26% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Biophytis S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €-25.51 | €0.02 | x |
| 2014-12-31 | €-73.72 | €0.02 | x |
| 2015-12-31 | €961.53 | €0.02 | x |
| 2016-12-31 | €293.35 | €0.02 | x |
| 2017-12-31 | €923.68 | €0.02 | x |
| 2018-12-31 | €210.46 | €0.02 | x |
| 2019-12-31 | €-178.64 | €0.02 | x |
| 2020-12-31 | €15.33 | €0.02 | x |
| 2021-12-31 | €19.73 | €0.02 | x |
| 2022-12-31 | €-4.30 | €0.02 | x |
| 2023-12-31 | €-2.84 | €0.02 | x |
| 2024-12-31 | €-1.86 | €0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biophytis S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-179.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | €-483.53K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | €-599.05K |
| 2015 | -44.73% | 0.00% | 0.00x | 1.16x | €-6.40 Million |
| 2016 | -174.85% | 0.00% | 0.00x | 1.85x | €-8.41 Million |
| 2017 | -53.77% | 0.00% | 0.00x | 1.22x | €-13.53 Million |
| 2018 | -198.76% | 0.00% | 0.00x | 3.11x | €-14.69 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | €-18.19 Million |
| 2020 | -1109.92% | 0.00% | 0.00x | 11.84x | €-25.75 Million |
| 2021 | -574.57% | 0.00% | 0.00x | 6.21x | €-34.11 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-24.03 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-16.64 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-9.41 Million |
Industry Comparison
This section compares Biophytis S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,457,609
- Average return on equity (ROE) among peers: -74.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biophytis S.A. (ALBPS) | €-7.82 Million | 0.00% | N/A | $1.03 Million |
| Abionyx Pharma SA (ABNX) | $7.42 Million | -59.27% | 0.81x | $123.48 Million |
| Abivax SA (ABVX) | $11.78 Million | -260.03% | 3.39x | $6.97 Billion |
| Adocia (ADOC) | $45.85 Million | 16.61% | 0.53x | $111.73 Million |
| Aelis Farma SA (AELIS) | $1.20 Million | -263.37% | 5.00x | $18.95 Million |
| Cellectis (ALCLS) | $450.27 Million | -17.48% | 0.11x | $282.27 Million |
| Advicenne (ALDVI) | $16.92 Million | -83.89% | 0.35x | $21.67 Million |
| Genoway (ALGEN) | $1.90 Million | 0.00% | 1.85x | $30.11 Million |
| Integragen (ALINT) | $2.19 Million | 0.70% | 3.39x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.42 Million | 0.00% | 0.00x | $1.80 Million |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more